Michael Yee

Answer

Alisha Alaimo, President & Head of North America, responded that Biogen views myostatin inhibitors as providing an additive benefit for SMA patients. She clarified that the company does not see them as a direct competitor to Spinraza or other existing SMN-modifying therapies and does not anticipate a significant issue for their franchise.

Ask Fintool Equity Research AI

Answer

Alisha Alaimo, President & Head of North America, responded that Biogen views myostatin inhibitors as a potential additive benefit for SMA patients. She clarified that the company does not see them as a direct competitor to Spinraza or other existing SMA therapies and does not anticipate them being a significant issue for the franchise.

Ask Fintool Equity Research AI

Answer

Head of Development Dr. Priya Singhal explained that the AHEAD 3-45 study is uniquely designed to assess LEQEMBI across the full spectrum of presymptomatic Alzheimer's, unlike competitor studies with mixed populations. CEO Christopher Viehbacher added that this design will provide crucial data on the risk-benefit of treating patients at different amyloid levels, which he believes will make it a landmark study for physicians.

Ask Fintool Equity Research AI

Answer

Dr. Priya Singhal, Head of Development, explained that an FDA-approved, widely reimbursed in-vitro diagnostic is a critical near-term catalyst to build physician confidence and streamline the care pathway. She noted that while triage tests exist, full approval and data demonstrating concordance with PET scans will be key for broad adoption.

Ask Fintool Equity Research AI

Answer

Dr. Priya Singhal, Head of Development, confirmed that enrollment for the study was completed in October. While the trial has a 216-week primary endpoint, she mentioned that Biogen is actively engaging with regulators to explore all options for when the study might read out and will provide future updates.

Ask Fintool Equity Research AI

Answer

CEO David Hallal positioned the study as an initial exploration of Scholar Rock's potential role in obesity. President of R&D Akshay Vaishnaw clarified that the readout's primary focus will be the 24-week data on lean mass changes and safety. He emphasized the importance of addressing muscle loss but did not commit to a specific quantitative benchmark for success.

Ask Fintool Equity Research AI

Answer

Executive Jay Backstrom clarified that at the 24-week timepoint, they expect total weight loss to be comparable between the combination arm and the placebo arm. He explained that the magnitude of weight loss from tirzepatide is so significant that any effect from muscle preservation on total weight would likely be a 'wash' at this early stage. However, he acknowledged the potential for incremental weight loss over a longer treatment period.

Ask Fintool Equity Research AI

Answer

Executive Jay Backstrom explained that the EMBRAZE trial is a proof-of-concept study using apitegromab to validate their selective anti-myostatin approach, with the primary endpoint being lean muscle mass at 24 weeks. This is intended to guide the development of SRK-439, which will be a subcutaneous formulation. He noted that for the EMBRAZE data, success would be defined by the preservation of lean muscle mass, which is considered clinically meaningful for improving the durability of weight loss, reducing fat mass, and enhancing glucose metabolism.

Ask Fintool Equity Research AI

Answer

CEO David Chang explained that a 3-to-4-month lag between site activation and patient screening was due to site-level staffing shortages, an issue now understood and improving. EVP of R&D and CMO Dr. Zachary Roberts clarified that the 250 consented patients represent the 'top of the funnel' for MRD screening, not final enrollment, but noted the strong consenting trend is a positive leading indicator for future enrollment.

Ask Fintool Equity Research AI

Answer

Dr. Zachary Roberts, EVP of R&D and CMO, stated the company is agnostic about needing ALLO-647, as both outcomes have benefits. He confirmed the H1 2026 interim analysis is a formal efficacy test on event-free survival with a minimal ALPHA spend, making a statistically significant finding possible, which could accelerate regulatory conversations.

Ask Fintool Equity Research AI

Answer

Dr. David Chang, President and CEO, addressed the autoimmune question, stating that while multiple modalities can coexist, allogeneic CAR-T offers the unique advantages of being an off-the-shelf, 'once-and-done' therapy, with ALLO-329 specifically designed to overcome the lymphodepletion hurdle. Dr. Zachary Roberts, EVP of R&D and CMO, commented on ALPHA3, noting 'through the roof' enthusiasm from clinical sites and that the trial is progressing as expected, with strong engagement from community centers.

Ask Fintool Equity Research AI

Answer

Joshua Smiley, President and COO, attributed the VYVGART sales dip to Chinese New Year seasonality affecting IV infusions and a Q4 inventory build for Hytrulo, but noted a strong rebound in April. Dr. Samantha Du, Founder and CEO, affirmed that Zai Lab maintains a high bar for business development but will actively pursue differentiated, high-potential assets for both regional and global rights.

Ask Fintool Equity Research AI

Answer

Joshua Smiley, President and COO, explained that VYVGART's growth will accelerate in the second half of 2025 due to the compounding effect of returning patients and an expected update to treatment guidelines. Dr. Rafael Amado, President and Head of Global R&D, added that for ZL-1310, they are in discussions with regulators for an accelerated approval pathway, plan to start a pivotal study in 2025, and are confident they are about 1.5 years ahead of competitors.

Ask Fintool Equity Research AI

Answer

President and COO Josh Smiley confirmed the company is on a trend to meet or exceed the $70 million VYVGART guidance but noted it's early to precisely model patient cycles. Executive Officer Jonathan Wang addressed business development, stating priorities are late-stage, de-risked regional deals and earlier-stage assets with global potential.

Ask Fintool Equity Research AI

Answer

Karen Akinsanya, President of R&D and Therapeutics, stated that the initial SGR-1505 data update will cover safety, pharmacokinetics (PK), and pharmacodynamics (PD), along with preliminary efficacy. Geoffrey Porges, CFO, addressed cash burn, noting he does not anticipate a substantial increase next year as the company maintains optionality with its lead programs.

Ask Fintool Equity Research AI

Answer

CEO Reshma Kewalramani explained that the VX-993 study will explore its full dose range to assess if it can improve upon JOURNAVX's efficacy and serve as an option for future combinations. CCO Duncan McKechnie clarified that third-party retail data doesn't capture hospital usage, and the total prescription number was 25,000. He noted that week-to-week variability is common early in a launch and that growth will increase with payer coverage.

Ask Fintool Equity Research AI

Answer

COO Stuart Arbuckle expressed high confidence in securing broad coverage over time across all payer segments. He cited the significant unmet need for effective non-opioids and supportive federal and state policy initiatives as key factors that should facilitate smooth market access for JOURNAVX.

Ask Fintool Equity Research AI

Answer

CEO Dr. Reshma Kewalramani explained that VX-993 supports serial innovation, enables an IV formulation, and provides optionality for a future NaV1.7 combination. On inaxaplin, she noted the current regulatory agreement is for an accelerated approval based on GFR slope, but acknowledged the positive evolution of regulatory discussions around proteinuria.

Ask Fintool Equity Research AI

Answer

Robert Bradway, CEO, expressed high confidence in MariTide's Phase III design, stating it was informed by Phase I and II data showing dose escalation improves tolerability without sacrificing efficacy. Murdo Gordon, EVP of Global Commercial Operations, added that while an oral market is expected, MariTide's monthly or less frequent dosing makes it less vulnerable to competition than weekly injectables.

Ask Fintool Equity Research AI

Answer

CEO Robert Bradway and EVP of R&D James Bradner refuted the idea of 'slip-ups,' clarifying that early-stage programs are held to a high bar. Dr. Bradner affirmed confidence in a deep pipeline behind MariTide, including oral and subcutaneous candidates with diverse mechanisms, and noted an openness to external partnerships.

Ask Fintool Equity Research AI

Answer

EVP of R&D James Bradner responded that while MariTide is the primary focus, Amgen is actively developing a broader portfolio. He confirmed the company is pursuing both injectable and oral medicines, as well as incretin and non-incretin mechanisms, to address the diverse needs of the obesity market.

Ask Fintool Equity Research AI

Answer

The company expects consistent underlying patient growth throughout the year, pointing to the updated annual guidance. They noted a specific calendar dynamic where an ordering day missed in Q1 is made up in Q3, which could shift some growth into that quarter.

Ask Fintool Equity Research AI

Answer

Chief Commercial Officer Johanna Mercier stated the team is ready for the launch following the anticipated June 19 PDUFA date. She projected that access would ramp to 75% of covered lives within six months and peak at 90% within a year, with initial access facilitated through medical exceptions. This gradual build-out is expected to support a strong launch trajectory through 2025 and into 2026.

Ask Fintool Equity Research AI

Answer

CEO Daniel O'Day stated that interactions with the FDA are on track for a summer approval, supported by its Breakthrough Therapy designation. CCO Johanna Mercier added that the European strategy involves a tiered, country-specific approach and highlighted the EU filing's importance for the EU-M4all initiative, which facilitates access in over 130 low- and middle-income countries.

Ask Fintool Equity Research AI

Answer

Johanna Mercier, Chief Commercial Officer, expressed high excitement for the launch, outlining clear growth opportunities in expanding the market size to new consumers (Black, Latino, women) and prescribers. She anticipates lenacapavir will impact both Descovy and the generic oral market. Mercier confirmed that commercialization plans are well underway to ensure a seamless experience for providers and consumers, with more details to be shared at the December HIV analyst event.

Ask Fintool Equity Research AI

Answer

President Stephen Hoge described a 2026 readout for the INT vaccine as 'possible, plausible' but emphasized it is event-driven and timing remains uncertain. For Norovirus, he explained that since the Northern Hemisphere cohort is fully enrolled and constitutes the majority of the study, it's possible that participants from the Southern Hemisphere may not be needed to hit the efficacy endpoint.

Ask Fintool Equity Research AI

Answer

President Stephen Hoge stated that discussions with the FDA are ongoing for the combo vaccine's BLA submission. CEO Stéphane Bancel addressed the RSV market, noting that lower-than-expected demand, new CDC guidelines, and significant channel inventory from competitors have impacted sales, but expressed confidence for 2025 with a full contracting season and ex-U.S. approvals.

Ask Fintool Equity Research AI

Answer

David Berman, Head of R&D, clarified that for the HIV trial, the focus of the Phase 1 dose escalation is not on a specific rate but on observing activity, noting a commercially successful target product profile (TPP) would involve suppressing viral copies to less than 200 copies/ml for two years in 20-30% of patients. Ralph Torbay, Head of Commercial, addressed European sales, attributing the performance to a challenging reimbursement environment and ongoing price negotiations in key markets like Germany and France.

Ask Fintool Equity Research AI

Answer

Ralph Torbay, Head of Commercial, explained the $6.7 million reserve was a 'onetime thing' based on negotiations with France and Germany but cautioned against simply adding it back in future quarters. David Berman, Head of R&D, stated that for the HIV program, seeing any biological activity is significant for a first-in-class therapy in a low-target-density setting. He confirmed they are enrolling more patients and exploring higher doses, with a full data release planned for Q1 2025.

Ask Fintool Equity Research AI

Answer

Ralph Torbay, Head of Commercial, explained the $6.7 million reserve was a one-time adjustment based on negotiations in France and Germany, cautioning it affects future periods as well. David Berman, Head of R&D, stated the HIV program shows biological activity at low target densities, and they are enrolling more patients and exploring higher doses before the Q1 2025 data release.

Ask Fintool Equity Research AI

Answer

The company expects the AFFIRM-AL control arm to behave similarly to the VITAL control arm (median survival ~8.3 months), as the ANDROMEDA data shows daratumumab does not impact early mortality in the first 15 months. The timing and nature of blinded events in AFFIRM-AL appear similar to VITAL. The question about PRX012 success criteria was not answered.

Ask Fintool Equity Research AI

Answer

President and CEO Gene G. Kinney clarified that they expect the control arm to perform similarly to the VITAL trial's control arm (approx. 8.3 months median survival), as data from the ANDROMEDA study suggests daratumumab does not impact early mortality. Chief Development Officer Chad Swanson added that blinded event data in AFFIRM-AL appears consistent with VITAL, supporting their powering assumptions. The question on PRX012 was not addressed in the response.

Ask Fintool Equity Research AI

Answer

President and CEO Gene G. Kinney clarified that the control arm is expected to behave similarly to the VITAL trial's control arm (median survival ~8.3 months), as daratumumab has not shown an impact on early mortality. Chief Development Officer Chad Swanson added that blinded event timing in AFFIRM-AL appears consistent with VITAL, reinforcing this expectation.

Ask Fintool Equity Research AI

Answer

CEO Gene G. Kinney stated they expect the control arm to behave similarly to the VITAL trial, where median survival was ~8.3 months, noting that daratumumab has not impacted early mortality in the ANDROMEDA study. Chief Development Officer Chad Swanson added that blinded event timing and nature in AFFIRM-AL appear similar to VITAL, reinforcing their assumptions.

Ask Fintool Equity Research AI

Answer

The study is double-blind, and the ARIA rates at 70mg were consistent with placebo. This favorable therapeutic index gives them the ability to move up in dose. All dose cohorts, including 200mg, are active, and they are exploring the full exposure-response relationship from 45mg to 400mg, indicating their belief in the potential for a best-in-class molecule.

Ask Fintool Equity Research AI

Answer

The company expects revenue growth to be driven by increased penetration in the immunocompromised population, which is not considered seasonal. They are early in their growth, so seasonality is not a major factor yet. Profitability will be driven by significant reductions in OpEx, primarily from the R&D line, as major manufacturing campaigns for PEMGARDA and VYD2311 are largely complete and were previously expensed.

Ask Fintool Equity Research AI

Answer

Chairman Marc Elia and CFO William Duke explained that a significant reduction in operating expenses is expected, driven primarily by lower R&D spend as major manufacturing campaigns for PEMGARDA and VYD2311, which were expensed through R&D, are now substantially complete. Chief Commercial Officer Timothy Lee addressed revenue, stating that seasonality is not a major factor for the core immunocompromised patient population and that the company is focused on driving deeper penetration, with Marc Elia adding that the launch is too early to see seasonal effects.

Ask Fintool Equity Research AI

Answer

Interim CEO Frederick Vogt responded that reimbursement time has been reduced to an average of 3 weeks, which aligns well with ATC scheduling needs and is not seen as a bottleneck. For the lung cancer trial (IOV-LUN-202), he reiterated that data is expected in 2025, with a potential U.S. approval in 2027.

Ask Fintool Equity Research AI

Answer

CEO John Evans confirmed the progress and reiterated guidance for a data release in 2025. He explained that the company is dose-escalating from a low but biologically active dose. He stated that data would be shared once a 'clear profile of the drug' emerges, which he indicated would mean results from at least multiple patient cohorts, and that the company would narrow the timing guidance when possible.

Ask Fintool Equity Research AI

Answer

CEO John Evans confirmed the first cohort is dosed and the trial is progressing, with initial data expected in 2025. He reiterated that the company plans to release data when a clear profile of the drug emerges, which would likely mean after results from multiple dose cohorts are available. He expressed confidence in the 2025 guidance for this data release.

Ask Fintool Equity Research AI

Answer

CEO John Evans confirmed the 2025 guidance for an initial data release. He stated the company would share data once a 'clear profile of the drug' emerges, which he suggested would mean results from at least multiple dose cohorts. Key data points will include levels of normal M alpha-1 protein, reduction of toxic Z protein, and safety.

Ask Fintool Equity Research AI

Answer

CEO Scott Wolchko explained that positive data from the FT819 oncology study using a non-fludarabine regimen provides confidence to amend the IND and add a Cytoxan-only option, enhancing physician choice. For FT522, he highlighted the extensive preclinical work supporting the no-conditioning arm. Dr. Bob Valamehr, Chief Research and Development Officer, added that preclinical data shows FT522 with ADR technology maintains persistence and targets B-cells effectively in an allogeneic system, and the trial will assess key biomarkers to inform the autoimmune strategy.

Ask Fintool Equity Research AI

Answer

President and CEO Stephen Mahoney described the FDA meeting for VRDN-003 as positive and reiterated guidance for a pivotal program start in mid-2024, pending receipt of official minutes. Chief Medical Officer Thomas Ciulla explained that for hearing, the study uses an exclusion criterion for baseline hearing loss, which is detailed on clinicaltrials.gov, in addition to standard monitoring via MedDRA terms and audiometry.

Ask Fintool Equity Research AI

Answer

President and CEO Benjamin Zeskind did not specify dose levels but pointed to the company's detailed data release schedule. Chief Scientific Officer Brett Hall described the PD modeling, which uses two orthogonal assays to measure MAP kinase pathway attenuation. Zeskind addressed safety, noting excellent preclinical tolerability and emphasizing that the drug's short half-life and high CMAX are designed to improve the therapeutic index compared to traditional MEK inhibitors.

Ask Fintool Equity Research AI